Product Name:Liraglutide
Cas No:204656-20-2
Molar Mass:3751.25
Chemical Formula:C172H265N43O51
Synonyms:NN 2211, Saxenda, Victoza
Storage:Store at -20°C
Sequence: HAEGTFTSDV SSYLEGQAAK EFIAWLVRGR G
Target Indicators:GLP-1
Application:
Liraglutide (CAS number 204656-20-2) is a prominent pharmaceutical compound widely utilized in the management of type 2 diabetes. As a glucagon-like peptide-1 receptor agonist (GLP-1 RA), Liraglutide mimics the action of endogenous GLP-1, stimulating glucose-dependent insulin secretion and inhibiting glucagon release. This dual mechanism leads to improved blood glucose control. Liraglutide is administered through injection and is known for its sustained efficacy, contributing to enhanced patient adherence. Beyond its primary role in glycemic management, Liraglutide has demonstrated cardiovascular benefits, further solidifying its position in comprehensive diabetes care. Moreover, its association with weight loss makes it particularly beneficial for individuals with diabetes who may also struggle with obesity. In the pharmaceutical realm, Liraglutide has become a cornerstone in the evolving landscape of diabetes therapeutics due to its multifaceted effects. The compound’s impact on both glycemic control and cardiovascular outcomes underscores its significance in optimizing patient health. With its well-established safety profile and demonstrated efficacy, Liraglutide continues to be a valuable asset in the arsenal against type 2 diabetes.
Current Research:Liraglutide, a GLP-1 analogue initially developed for glycemic control, has emerged as a promising anti-obesity therapy. Obesity, a chronic and multifactorial disease, stems from dysregulated energy balance leading to excessive fat accumulation. Adipocyte hypertrophy and increased adipose depots contribute to chronic inflammation, characterized by elevated levels of pro-inflammatory markers like TNF-α and other adipokines. Additionally, factors such as food intake, caloric content, and nutrient absorption influence weight gain, with the gastrointestinal (GI) tract playing a pivotal role in regulating hunger and satiety. Resistant to enzymatic degradation, liraglutide binds to GLP-1 receptors in various tissues, including the GI tract, where it modulates appetite, food intake, and GI secretion and motility. While the exact mechanisms are still under investigation, preclinical studies suggest that GLP-1 analogues possess anti-inflammatory properties, potentially impacting GI motility and inflammation associated with obesity. To elucidate liraglutide’s effects on metabolism and GI function in obesity, a rat model study was conducted. Liraglutide treatment resulted in decreased gastric motility, possibly contributing to reduced food intake and weight loss. Moreover, liraglutide decreased fat tissue deposition, particularly in visceral fat depots known for their inflammatory activity. Notably, liraglutide treatment downregulated inflammatory signaling pathways, as evidenced by decreased levels of TNF-α, a pro-inflammatory cytokine, and increased levels of TGF-β1, which promotes mucosal integrity and epithelial barrier repair in the GI tract. Furthermore, liraglutide treatment led to improvements in liver function and metabolic parameters associated with obesity-related complications like non-alcoholic fatty liver disease (NAFLD). These beneficial effects on hepatic and cardiovascular functions were attributed to liraglutide’s anti-inflammatory and antioxidant properties, independent of changes in body weight. Despite the study’s limitations, including short-term treatment duration, the findings highlight liraglutide’s efficacy in controlling obesity-related outcomes by reducing caloric intake, adiposity, and inflammation while improving metabolic parameters. These results underscore the potential of GLP-1 analogue therapy, particularly liraglutide, in the long-term management of obesity and its associated complications, offering new insights into its clinical use and therapeutic benefits.
